USP7-IN-18

• Target :

  DUB|||DNA Methyltransferase|||MDM-2/p53

• Related Pathways :

  Chromatin/Epigenetic|||DNA Damage/DNA Repair|||Ubiquitination|||Cell Cycle/Checkpoint|||Apoptosis

• Bioactivity :

  USP7-IN-18 (Compound X21) serves as a novel USP7 inhibitor by directly suppressing enzyme activity and modulating downstream pathways, including the newly identified PCLAF target. At concentrations of 0.25-1 ?M for 24 hours, it exhibits inhibitory effects. USP7-IN-18 effectively reduces proliferation in leukemia (RS4;11) and colon cancer (MC38/CT26.WT) cells at 0.01-100 ?M over 72 hours. It demonstrates high selectivity for USP7 at 2.5 ?M within 0.5 hours, surpassing eight other deubiquitinating enzymes. SPR analysis shows that at 1.95-2000 nM for 3 minutes, the compound binds the catalytic domain of USP7 with a KD value of 4.9 ?M.

• Smiles :

  O=C1N(C(=O)C2C1C2(C)C)CC=3SC=4C(=NC=CC4C5=CC(Cl)=C6C=CC=CC6=C5OC7CCNCC7)C3

• Molecular Formula :

  C30H28ClN3O3S

• Molecular Weight :

  546.08

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C

• CAS Number :

  3052223-40-9